Spero Therapeutics CEO Ankit Mahadevia's 2021 pay jumps 130% to $4.9M
Spero Therapeutics reports 2021 executive compensation
By ExecPay News
Published: August 5, 2022
Spero Therapeutics reported fiscal year 2021 executive compensation information on August 5, 2022.
In 2021, four executives at Spero Therapeutics received on average a compensation package of $2.5M, a 60% increase compared to previous year.
Average pay of disclosed executives at Spero Therapeutics
Ankit Mahadevia, Chief Executive Officer, received $4.9M in total, which increased by 130% compared to 2020. 54% of Mahadevia's compensation, or $2.7M, was in option awards. Mahadevia also received $328K in non-equity incentive plan, $590K in salary, $1.3M in stock awards, as well as $6.2K in other compensation.
Satyavrat Shukla, Chief Financial Officer, received a compensation package of $2.2M. 47% of the compensation package, or $1M, was in option awards.
Cristina Larkin, Chief Operating Officer, earned $1.9M in 2021, a 92% increase compared to previous year.
Tamara Joseph, Chief Legal Officer, received $980K in 2021.
Related executives
You may also like
Source: SEC filing on August 5, 2022.